Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daré Bioscience, Inc. filings document a women’s health biotechnology issuer with product and pipeline disclosures, operating-result updates, and capital-structure activity. Recent 8-K reports cover financial results, Regulation FD presentations, and unregistered sales tied to a Regulation A unit offering composed of Series A Convertible Preferred Stock and warrants to purchase common stock.
Proxy and governance filings describe annual meeting matters, director elections, executive compensation, equity awards, board classification, and stockholder voting procedures. The record also includes disclosure around offering statements, preferred-stock conversion terms, warrant exercise terms, and financing activity associated with advancing women’s health products and clinical programs.
Dare Bioscience (NASDAQ:DARE) disclosed that Nasdaq's Hearings Panel has amended its decision regarding the company's delisting appeal and approved their modified compliance plan. The company must demonstrate compliance with either the $2.5 million stockholders' equity requirement or maintain a $35 million minimum market value by July 31, 2025, with a final deadline of August 12, 2025. Dare has been non-compliant with these requirements since August 2024. The Panel reserves the right to delist the stock before the deadline if the company fails to execute its plan satisfactorily.